Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

Global cancer statistics

Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679

Global Cancer Statistics, 2002

Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993

Pten is essential for embryonic development and tumour suppression

Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109

Essential role for nuclear PTEN in maintaining chromosomal integrity

Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., & Parsons, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1563 · Cited by 946

The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications

Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W., & Leal, J. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908784293659 · Cited by 887

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844

Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry

Ehrich, M., Nelson, M. R., Stanssens, P., Zabeau, M., Liloglou, T., Xinarianos, G., Cantor, C. R., Field, J. K., & van den Boom, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507816102 · Cited by 812

P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase

Myers, M. P., Stolarov, J. P., Eng, C., Li, J., Wang, S. I., Wigler, M. H., Parsons, R., & Tonks, N. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9052 · Cited by 775

Ubiquitination regulates PTEN nuclear import and tumor suppression

Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748

Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., & Sidransky, D. (1997) · PubMed · Cited by 700

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer

Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., et al. (2008) · Neoplasia · doi:10.1593/neo.07822 · Cited by 690

Pten Dose Dictates Cancer Progression in the Prostate

Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 676

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659

Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

McMenamin, M. E., Soung, P., Perera, S., Kaplan, I. D., Loda, M. F., & Sellers, W. R. (1999) · PubMed · Cited by 640

Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse

Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., & P Pandolfi, P. (2001) · Nature Genetics · doi:10.1038/84879 · Cited by 498

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.371 · Cited by 477

Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.

Suzuki, H., Freije, D., Nusskern, D. R., Okami, K., Cairns, P., Sidransky, D., Isaacs, W. B., & Bova, G. S. (1998) · PubMed · Cited by 452

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

Lotan, T. L., Gurel, B., Sutcliffe, S., Esopi, D., Liu, W., Xu, J., Hicks, J. L., Park, B. H., Humphreys, E., Partin, A. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1244 · Cited by 348

Akt-regulated pathways in prostate cancer

Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344

Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression

Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., & Ittmann, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201167798 · Cited by 323

Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 Accumulation

Visakorpi, T., Kallioniemi, O.-P., Heikkinen, A., Koivula, T., & Isola, J. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.11.883 · Cited by 304

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome

Yoshimoto, M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Torres, C. H., Soares, F. A., & Squire, J. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603924 · Cited by 295

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

Yoshimoto, M., Joshua, A. M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Ludkovski, O., Zielenska, M., Soares, F. A., & Squire, J. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.96 · Cited by 279

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

on behalf of the Transatlantic Prostate Group, Reid, A. H. M., Attard, G., Ambroisine, L., Fisher, G., Kovacs, G., Brewer, D., Clark, J., Flohr, P., Edwards, S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605554 · Cited by 250

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

Minner, S., Enodien, M., Sirma, H., Luebke, A. M., Krohn, A., Mayer, P. S., Simon, R., Tennstedt, P., Müller, J., Scholz, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1251 · Cited by 249

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

Han, B., Mehra, R., Lonigro, R. J., Wang, L., Suleman, K., Menon, A., Palanisamy, N., Tomlins, S. A., Chinnaiyan, A. M., & Shah, R. B. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.69 · Cited by 227

PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

Sircar, K., Yoshimoto, M., Monzon, F. A., Koumakpayi, I. H., Katz, R. L., Khanna, A., Alvarez, K., Chen, G., Darnel, A. D., Aprikian, A. G., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2559 · Cited by 208

ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells

Zong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905931106 · Cited by 203

Clinical significance of p53 alterations in surgically treated prostate cancers

Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Köllermann, J., Minner, S., Passow-Drolet, A., Mirlacher, M., Milde-Langosch, K., Graefen, M., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.104 · Cited by 196

Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias

Yoshimoto, M., Cutz, J.-C., Nuin, P. A. S., Joshua, A. M., Bayani, J., Evans, A. J., Zielenska, M., & Squire, J. A. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.04.003 · Cited by 181

Expression patterns of potential therapeutic targets in prostate cancer

Zellweger, T., Ninck, C., Bloch, M., Mirlacher, M., Koivisto, P. A., Helin, H. J., Mihatsch, M. J., Gasser, T. C., & Bubendorf, L. (2005) · International Journal of Cancer · doi:10.1002/ijc.20615 · Cited by 165

Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation

Bedolla, R. G., Prihoda, T. J., Kreisberg, J. I., Malik, S. N., Krishnegowda, N. K., Troyer, D. A., & Ghosh, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0091 · Cited by 149

Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer

Gammal, A. E. E., Brüchmann, M., Zustin, J., Isbarn, H., Hellwinkel, O., Köllermann, J., Sauter, G., Simon, R., Wilczak, W., Schwarz, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1423 · Cited by 146

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

Minner, S. J. P., Jessen, B., Stiedenroth, L., Burandt, E., Köllermann, J. W., Mirlacher, M., Erbersdobler, A., Eichelberg, C., Fisch, M., Brümmendorf, T. H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2546 · Cited by 144

Is PTEN loss associated with clinical outcome measures in human prostate cancer?

McCall, P. J., Witton, C. J., Grimsley, S. J. S., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604680 · Cited by 135

Haplo‐insufficiency: a driving force in cancer

Berger, A. H., & Pandolfi, P. P. (2010) · The Journal of Pathology · doi:10.1002/path.2800 · Cited by 131

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

Bismar, T. A., Yoshimoto, M., Vollmer, R. T., Duan, Q., Firszt, M., Corcos, J., & Squire, J. A. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09470.x · Cited by 121

The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness

Kotelevets, L., van Hengel, J., Bruyneel, E. A., Mareel, M. M. K., Roy, F. M. V., & Chastre, E. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200105109 · Cited by 118

The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion

Verhagen, P. C. M. S., van Duijn, P. W., Hermans, K., Looijenga, L. H. J., van Gurp, R., Stoop, H., van der Kwast, T., & Trapman, J. (2006) · The Journal of Pathology · doi:10.1002/path.1929 · Cited by 108

PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate

Dong, J., Sipe, T. W., Hyytinen, E., Li, C., Heise, C. E., McClintock, D. E., Grant, C. D., Chung, L. W. K., & Frierson, H. F. (1998) · Oncogene · doi:10.1038/sj.onc.1202119 · Cited by 100

Loss of PTEN is associated with progression to androgen independence

Bertram, J., Peacock, J. W., Fazli, L., Mui, A., Chung, S. W., Cox, M., Monia, B. P., Gleave, M. E., & Ong, C. J. (2006) · The Prostate · doi:10.1002/pros.20411 · Cited by 81

Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer

THOMAS, G. V., Horvath, S., Smith, B. L., Crosby, K., Lebel, L. A., Schrage, M. I., Said, J. W., Kernion, J. D., Reiter, R. E., & Sawyers, C. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0130 · Cited by 72

A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors

Sangale, Z., Prass, C. E., Carlson, A., Tikishvili, E., DeGrado, J., Lanchbury, J. S. S., & Stone, S. (2010) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181f1da13 · Cited by 69

Immunohistochemical Detection of p53 Protein in Human Prostatic Cancer

Henke, R., Krüger, E., Ayhan, N., Hübner, D., Hammerer, P. G., & Huland, H. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)32571-5 · Cited by 62

Cdc6 and Cyclin E2 Are PTEN-Regulated Genes Associated with Human Prostate Cancer Metastasis

Wu, Z., Cho, H., Hampton, G. M., & Theodorescu, D. (2009) · Neoplasia · doi:10.1593/neo.81048 · Cited by 51

Gain of Function of p53 Cancer Mutants in Disrupting Critical DNA Damage Response Pathways

Song, H., & Xu, Y. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4456 · Cited by 50

Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer

Couto, S. S., Cao, M., Duarte, P. C. X., Banach-Petrosky, W. A., Wang, S., Romanienko, P. J., Wu, H., Cardiff, R. D., Abate-Shen, C. T., & Cunha, G. R. (2009) · Differentiation · doi:10.1016/j.diff.2008.09.010 · Cited by 39

Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications

Müller, I., Wischnewski, F., Pantel, K., & Schwarzenbach, H. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-297 · Cited by 37

The role of PTEN in prostate cancer cell tropism to the bone micro-environment

Wu, Z.-N., McRoberts, K., & Theodorescu, D. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm050 · Cited by 36

Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression

Osman, I., Dai, J., Mikhail, M., Navarro, D., Taneja, S. S., Lee, P., Christos, P. J., Shen, R., & Nanus, D. M. (2006) · Cancer · doi:10.1002/cncr.22312 · Cited by 34

FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context

Mäder, M., Simon, R., Steinbiss, S., & Kurtz, S. (2011) · Journal of Clinical Bioinformatics · doi:10.1186/2043-9113-1-20 · Cited by 14

Mechanisms of PTEN loss in cancer: It’s all about diversity

Álvarez-Garcia, V., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.001 · Cited by 401

Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer

Weischenfeldt, J., Simon, R., Feuerbach, L., Schlangen, K., Weichenhan, D., Minner, S., Wuttig, D., Warnatz, H.-J., Stehr, H., Rausch, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.002 · Cited by 320

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.027 · Cited by 268

A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer

Ahearn, T. U., Pettersson, A., Ebot, E. M., Gerke, T., Graff, R. E., Morais, C. L., Hicks, J. L., Wilson, K. M., Rider, J. R., Sesso, H. D., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv346 · Cited by 186

PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo

Parisotto, M., Grelet, E., El Bizri, R., Dai, Y., Terzic, J., Eckert, D., Gargowitsch, L., Bornert, J.-M., & Metzger, D. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171207 · Cited by 43